INT8064

Context Info Confidence 0.28 First Reported 1992 Last Reported 2006 Negated 0 Speculated 0 Reported most in Body Documents 2 Total Number 2 Disease Relevance 0.83 Pain Relevance 0.22

cell differentiation (RASGRP1) Golgi apparatus (RASGRP1) endoplasmic reticulum (RASGRP1) cytoplasm (RASGRP1) cytosol (RASGRP1) lipid binding (RASGRP1)

Anatomy Link Frequency plasma 2 brain 2 RASGRP1 (Homo sapiens)

Pain Link Frequency Relevance Heat antagonist 1 93.92 Pain 2 85.28 Neurotransmitter 1 74.36 palliative 3 5.00 dexamethasone 2 5.00 Spinal cord 1 5.00 Analgesic 1 5.00 Intractable pain 1 5.00 addiction 1 5.00 Kinase C 1 5.00

Disease Link Frequency Relevance Heat Hypertension 5 100.00 Cancer 12 89.24 Pain 2 85.28 Apoptosis 8 73.04 Lung Cancer 2 68.32 Breast Cancer 25 50.00 Metastasis 11 49.52 Malignant Neoplastic Disease 3 41.48 Bone Cancer 3 39.24 Hypercalcemia 3 36.36

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Oral treatment with angiotensin-converting enzyme inhibitors, which interfere with the formation of angiotensin II, prevents the development of hypertension in young SHR by acting, at least in part, upon the brain RAS.

Negative_regulation (prevents) of RAS Binding (acting) of in brain associated with hypertension

1) Confidence 0.28 Published 1992 Journal Brain Res. Brain Res. Rev. Section Abstract Doc Link 1361394 Disease Relevance 0.55 Pain Relevance 0.17

The blockade of Ras binding to the plasma membrane may therefore be a good therapeutic target for the treatment of malignancies [22].

Negative_regulation (blockade) of Ras Binding (binding) of in plasma

2) Confidence 0.14 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779467 Disease Relevance 0.28 Pain Relevance 0.05

General Comments

This test has worked.